Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 6
2003 2
2004 5
2005 9
2006 9
2007 8
2008 10
2009 9
2010 7
2011 15
2012 13
2013 10
2014 11
2015 8
2016 13
2017 14
2018 13
2019 10
2020 14
2021 13
2022 10
Text availability
Article attribute
Article type
Publication date

Search Results

182 results
Results by year
Filters applied: . Clear all
Page 1
Splicing factor YBX1 mediates persistence of JAK2-mutated neoplasms.
Jayavelu AK, Schnöder TM, Perner F, Herzog C, Meiler A, Krishnamoorthy G, Huber N, Mohr J, Edelmann-Stephan B, Austin R, Brandt S, Palandri F, Schröder N, Isermann B, Edlich F, Sinha AU, Ungelenk M, Hübner CA, Zeiser R, Rahmig S, Waskow C, Coldham I, Ernst T, Hochhaus A, Jilg S, Jost PJ, Mullally A, Bullinger L, Mertens PR, Lane SW, Mann M, Heidel FH. Jayavelu AK, et al. Among authors: mertens pr. Nature. 2020 Dec;588(7836):157-163. doi: 10.1038/s41586-020-2968-3. Epub 2020 Nov 25. Nature. 2020. PMID: 33239784
Intensive Supportive Care plus Immunosuppression in IgA Nephropathy.
Rauen T, Eitner F, Fitzner C, Sommerer C, Zeier M, Otte B, Panzer U, Peters H, Benck U, Mertens PR, Kuhlmann U, Witzke O, Gross O, Vielhauer V, Mann JF, Hilgers RD, Floege J; STOP-IgAN Investigators. Rauen T, et al. Among authors: mertens pr. N Engl J Med. 2015 Dec 3;373(23):2225-36. doi: 10.1056/NEJMoa1415463. N Engl J Med. 2015. PMID: 26630142 Free article. Clinical Trial.
Additional Information Necessary.
Mertens PR. Mertens PR. Dtsch Arztebl Int. 2021 Jan 11;118(1-2):11-12. doi: 10.3238/arztebl.m2021.0045. Dtsch Arztebl Int. 2021. PMID: 33750529 Free PMC article. No abstract available.
After ten years of follow-up, no difference between supportive care plus immunosuppression and supportive care alone in IgA nephropathy.
Rauen T, Wied S, Fitzner C, Eitner F, Sommerer C, Zeier M, Otte B, Panzer U, Budde K, Benck U, Mertens PR, Kuhlmann U, Witzke O, Gross O, Vielhauer V, Mann JFE, Hilgers RD, Floege J; STOP-IgAN Investigators. Rauen T, et al. Among authors: mertens pr. Kidney Int. 2020 Oct;98(4):1044-1052. doi: 10.1016/j.kint.2020.04.046. Epub 2020 May 22. Kidney Int. 2020. PMID: 32450154 Clinical Trial.
[The Cardiorenal Syndrome].
Scurt FG, Kuczera T, Mertens PR, Chatzikyrkou C. Scurt FG, et al. Dtsch Med Wochenschr. 2019 Jul;144(13):910-916. doi: 10.1055/a-0768-5899. Epub 2019 Jun 28. Dtsch Med Wochenschr. 2019. PMID: 31252445 German.
Follistatin-controlled activin-HNF4α-coagulation factor axis in liver progenitor cells determines outcome of acute liver failure.
Lin T, Wang S, Munker S, Jung K, Macías-Rodríguez RU, Ruiz-Margáin A, Schierwagen R, Liu H, Shao C, Fan C, Feng R, Yuan X, Wang S, Wandrer F, Meyer C, Wimmer R, Liebe R, Kroll J, Zhang L, Schiergens T, Ten Dijke P, Teufel A, Marx A, Mertens PR, Wang H, Ebert MPA, Bantel H, N De Toni E, Trebicka J, Dooley S, Shin D, Ding H, Weng HL. Lin T, et al. Among authors: mertens pr. Hepatology. 2022 Feb;75(2):322-337. doi: 10.1002/hep.32119. Epub 2021 Dec 14. Hepatology. 2022. PMID: 34435364
Relevance of Notch Signaling for Bone Metabolism and Regeneration.
Ballhause TM, Jiang S, Baranowsky A, Brandt S, Mertens PR, Frosch KH, Yorgan T, Keller J. Ballhause TM, et al. Among authors: mertens pr. Int J Mol Sci. 2021 Jan 29;22(3):1325. doi: 10.3390/ijms22031325. Int J Mol Sci. 2021. PMID: 33572704 Free PMC article. Review.
Novel Insights into YB-1 Signaling and Cell Death Decisions.
Shah A, Lindquist JA, Rosendahl L, Schmitz I, Mertens PR. Shah A, et al. Among authors: mertens pr. Cancers (Basel). 2021 Jul 1;13(13):3306. doi: 10.3390/cancers13133306. Cancers (Basel). 2021. PMID: 34282755 Free PMC article. Review.
Thyroid hormone status in patients with impaired kidney function.
Peters J, Roumeliotis S, Mertens PR, Liakopoulos V. Peters J, et al. Among authors: mertens pr. Int Urol Nephrol. 2021 Nov;53(11):2349-2358. doi: 10.1007/s11255-021-02800-2. Epub 2021 Mar 8. Int Urol Nephrol. 2021. PMID: 33682051
Stem Cells for Next Level Toxicity Testing in the 21st Century.
Fritsche E, Haarmann-Stemmann T, Kapr J, Galanjuk S, Hartmann J, Mertens PR, Kämpfer AAM, Schins RPF, Tigges J, Koch K. Fritsche E, et al. Among authors: mertens pr. Small. 2021 Apr;17(15):e2006252. doi: 10.1002/smll.202006252. Epub 2020 Dec 23. Small. 2021. PMID: 33354870 Review.
182 results